Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor

被引：24

作者：

Beswick, Paul J. ^{[1
]}

Billinton, Andy ^{[1
]}

Chambers, Laura J. ^{[1
]}

Dean, David K. ^{[1
]}

Fonfria, Elena ^{[1
]}

Gleave, Robert J. ^{[1
]}

Medhurst, Stephen J. ^{[1
]}

Michel, Anton D. ^{[1
]}

Moses, Andrew P. ^{[1
]}

Patel, Sadhana ^{[1
]}

Roman, Shilina A. ^{[1
]}

Roomans, Sue ^{[1
]}

Senger, Stefan ^{[1
]}

Stevens, Alexander J. ^{[1
]}

Walter, Daryl S. ^{[1
]}

机构：

[1] GlaxoSmithKline, Neurosci Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 15期

关键词：

P2X(7); SAR; Pain; PAIN; MODEL;

D O I：

10.1016/j.bmcl.2010.05.107

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Structure-activity relationships (SAR) of analogues of lead compound 1 were investigated and compound 16 was selected for further study in animal models of pain. Compound 16 was shown to be a potent anti-hyperalgesic agent in both the rat acute complete Freund's adjuvant (CFA) model of inflammatory pain [Iadarola, M. J.; Douglass, J.; Civelli, O.; Naranjo, J. R. rain Res. 1988, 455, 205] and the knee joint model of chronic inflammatory pain [Wilson, A. W.; Medhurst, S. J.; Dixon, C. I.; Bontoft, N. C.; Winyard, L. A.; Brackenborough, K. T.; De Alba, J.; Clarke, C. J.; Gunthorpe, M. J.; Hicks, G. A.; Bountra, C.; McQueen, D. S.; Chessell, I. P. Eur. J. Pain 2006, 10, 537]. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：4653 / 4656

页数：4

共 22 条

[1] Ligand efficiency indices for effective drug discovery [J].

Abad-Zapatero, Cele .

EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (04) :469-488

[2]

Beswick P.J., 2007, PCT Appl. N. Patent, Patent No. [WO2007/141267, 2007141267]

[3]

Beswick P.J., 2008, PCT Appl. N. PCT App N, Patent No. [WO 2008/125600, 2008125600]

[4] Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation [J].

Broom, Daniel C. ;

Matson, David J. ;

Bradshaw, Elizabeth ;

Buck, Marianne E. ;

Meade, Robin ;

Coombs, Susan ;

Matchett, Michele ;

Ford, Kristen K. ;

Yu, Weifeng ;

Yuan, Jun ;

Sun, Synthia H. ;

Ochoa, Ricardo ;

Krause, James E. ;

Wustrow, David J. ;

Cortright, Daniel N. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) :620-633

[5] EXTRACELLULAR ATP INDUCES A LARGE NONSELECTIVE CONDUCTANCE IN MACROPHAGE PLASMA-MEMBRANES [J].

BUISMAN, HP ;

STEINBERG, TH ;

FISCHBARG, J ;

SILVERSTEIN, SC ;

VOGELZANG, SA ;

INCE, C ;

YPEY, DL ;

LEIJH, PCJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (21) :7988-7992

[6] Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor [J].

Chambers, Laura J. ;

Stevens, Alexander J. ;

Moses, Andrew P. ;

Michel, Anton D. ;

Walter, Daryl S. ;

Davies, David J. ;

Livermore, David G. ;

Fonfria, Elena ;

Demont, Emmanuel H. ;

Vimal, Mythily ;

Theobald, Pam J. ;

Beswick, Paul J. ;

Gleave, Robert J. ;

Roman, Shilina A. ;

Senger, Stefan .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (10) :3161-3164

[7] Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain [J].

Chessell, IP ;

Hatcher, JP ;

Bountra, C ;

Michel, AD ;

Hughes, JP ;

Green, P ;

Egerton, J ;

Murfin, M ;

Richardson, J ;

Peck, WL ;

Grahames, CBA ;

Casula, MA ;

Yiangou, Y ;

Birch, R ;

Anand, P ;

Buell, GN .

PAIN, 2005, 114 (03) :386-396

[8] Utility of metabolic stability screening:: comparison of in vitro and in vivo clearance [J].

Clarke, SE ;

Jeffrey, P .

XENOBIOTICA, 2001, 31 (8-9) :591-598

[9]

*CLINICALTRIAL GOV, NCT00628095 CLINICAL

[10] Tissue distribution of the P2X(7) receptor [J].

Collo, G ;

Neidhart, S ;

Kawashima, E ;

KoscoVilbois, M ;

North, RA ;

Buell, G .

NEUROPHARMACOLOGY, 1997, 36 (09) :1277-1283

← 1 2 3 →